MinhTri Nguyen, Medical Oncologist and Hematologist, shared a post on LinkedIn:
“We are faced with a good problem: more options and more data when it comes to the increasing options of oral SERDs available.
Join me in discussing EMERALD vs EMBER-3 and what these studies may teach us about differentiating the current oral SERDs approved today in ESR1-mutated HR+ metastatic breast cancer.
In the video, I walk through key trial differences one may apply to real-world treatment decisions.
It is an exciting time in breast oncology as we refine how to personalize therapy for our patients.
Watch here.”